---
title: "Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration"
description: "New Positive Preclinical Data Shows Succesful Drug Distribution to Liver, Peritoneum, and Lung with Measurable Reductions in Tumor Burden at Clinically Relevant Doses ..."
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/256914425.md"
published_at: "2025-09-11T11:38:39.000Z"
---

# Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration

> New Positive Preclinical Data Shows Succesful Drug Distribution to Liver, Peritoneum, and Lung with Measurable Reductions in Tumor Burden at Clinically Relevant Doses ...

New Positive Preclinical Data Shows Succesful Drug Distribution to Liver, Peritoneum, and Lung with Measurable Reductions in Tumor Burden at Clinically Relevant Doses ...

### Related Stocks

- [SLXN.US - Silexion Therapeutics](https://longbridge.com/en/quote/SLXN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Silexion Reports Positive Preclinical Data Demonstrating SIL204's Reach | Sept 11 (Reuters) - Silexion Therapeutics Corp:SILEXION THERAPEUTICS REPORTS POSITIVE PRECLINICAL DATA DEMONSTRATING SIL | [Link](https://longbridge.com/en/news/256907389.md) |
| Silexion Therapeutics Publishes 2025 Shareholder Letter Highlighting Major Achievements | Silexion Therapeutics Corp. has published a shareholder letter from CEO Ilan Hadar, highlighting major achievements in 2 | [Link](https://longbridge.com/en/news/271656749.md) |
| Forget AI stocks: This pharma giant is using AI to dominate drug discovery | And there's more than one way to monetize this technology. | [Link](https://longbridge.com/en/news/276017486.md) |
| Cause of death for Catherine O'Hara identified | Catherine O'Hara's cause of death has been identified as pulmonary embolism, with rectal cancer as an underlying factor. | [Link](https://longbridge.com/en/news/275452756.md) |
| Revolution Medicines Conference: CEO Details Daraxonrasib Phase III Timeline, First-Line PDAC Push | Revolution Medicines CEO Mark Goldsmith discussed the Phase III timeline for daraxonrasib, a RAS(ON) inhibitor, during a | [Link](https://longbridge.com/en/news/275992906.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
